Announced Fri, 24 Jul · 14:55 IST
Laurus Labs Q1 FY27 results: Revenue up 29%, EBITDA margins at 31.8%
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+9.0%1-day move
₹1570.00
prior close
₹1596.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.2-0.0+0.6+9.0—————————
Up moveDown movePending
AI summary
Q1 FY27: Revenue at Rs 2,026 Cr, up 29% YoY, driven by robust CDMO growth (up 67% to Rs 870 Cr) and Affordable Medicines (up 10%). EBITDA at Rs 644 Cr, margins 31.8% (up 700 bps YoY) on better mix and operational leverage. Net profit Rs 368 Cr, up 126% YoY. EPS Rs 6.8. Gross margins 62.7% (up 330 bps). CAPEX at 19% of revenue. Over 125 active CDMO projects, healthy order book. Cumulative FY22-27 CAPEX over Rs 4,700 Cr.
Likely market impact
Strong margin expansion of 700 bps and profit doubling YoY signal improving earnings quality. CDMO momentum positive for outlook.